CLINICAL_TRIALS
trial_result
· 2013-05-14
Clinical Trial Update: Phase IC Study of Safety and PK of SQ109 300mg Daily [Phase 1]
Summary
A Phase I trial evaluated the safety and pharmacokinetics of SQ109 at 300 mg daily for tuberculosis. The study has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED